Cue Biopharma (CUE) stock
Market cap $228M
Market closed. Prices as of Friday's close.
Follow CUE's news. Members get an alert when Cue Biopharma files news, and see its trials, share raises, and its CEO's filings.
What's next for CUE, and how long its cash lasts
From Cue Biopharma’s SEC filings and ClinicalTrials.gov: the company’s own words and the arithmetic, not a forecast. Companies often miss their own dates.
Next step the company has named
For members: 2 more milestones and 38 filings.
Cash runway to Jun 30
About 1 quarter
For members: the share count, 3 raises, 4 shelf filings, and the math.
For members: their 11 filings and quotes, and an alert each time they file.
FDA dates in the next 60 days
Decision dates and advisory committee meetings the companies have announced in their own filings, soonest first.
Why it's down
Fell 24% on Sep 21.
Its industry held up: the 259 other stocks in it were flat that day.
−2Dilution 99.3% more shares outstanding than a year ago
5 more things pulling CUE's score down, for members
What's next
Expected to report Wed Nov 11, after the close
After its last 3 reports it closed -13.1% on average, higher 0 of 3 times.
What would turn CUE's score around: 7 things, for members
Here is what members see.
Every stock gets a card like this one, and a page with its price in real time, every line of its score, the chart, and its filings.
CUE has 4 of a possible 13 checks firing
14 checks. Two are opposites (heavy volume and quiet volume), so at most 13 are on at once. One per group is shown here.
How CUE ranks in Biotech
CUE is #79 of 260 by Quality Score. The top three are shown with their scores, and the rest by name.
- 1
TGTXTG Therapeutics8/1319
- 2
RGENRepligen7/1319
- 3
HALOHalozyme Therapeutics7/1319
EXELExelixisOpen for its score
ONCBeOne MedicinesOpen for its score
- 79
CUECue Biopharma4/133
When does CUE report, and what happens after?
Expected to report Wed Nov 11, after the close (in 45 days). Not yet confirmed by the company.
| Reported | When | Gap | Reaction | 5 sessions |
|---|---|---|---|---|
| Aug 14, 2026After close | After close | -8.9% | -19.2% | -29.9% |
| Mar 16, 2026After close | After close | -4.7% | -12.8% | -14.5% |
| Nov 12, 2025After close | After close | -0.4% | -7.2% | -13.1% |
The gap is the next open against the close before the report; the reaction is where that session closed. CUE closed higher after 0 of its last 3. Past behavior, not a forecast.
Report dates and past reactions come from sessions that have already closed, so none of these figures move.
Who is trading CUE
Insiders
3 insiders sold $2M across 11 filings in the last 6 months. No open-market buys on record. The newest:
An insider has two business days to file a Form 4, so the trade is already days old when it becomes public. Shown as filed, with no delay.
About Cue Biopharma
Cue Biopharma Inc is a clinical-stage therapeutics company focused on advancing a robust portfolio of potentially transformative therapies aimed at enabling functional cures across immunological disorders. Its product pipeline includes CUE-221, an anti-IgE antibody candidate being developed for allergic diseases. The company has also developed the Immuno-STAT platform for targeting disease-related T cells and is developing CUE-401, an IL-2 and TGF-B therapeutic candidate for autoimmune diseases.
Every line of the score, on every stock.
- Real-time prices, no delay
- Every line of CUE's score, with the points and the reason
- All 14 checks on CUE and on all 2,950 stocks
- Every stock ranked, with the chart
- Every filing, and optional alerts on CUE
What a filing on CUE would have sent. Alerts are optional.
Straight answers.
Are the prices delayed?
Only on the public pages, which run at least 15 minutes behind. Members, trial included, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Where does the data come from?
Daily bars, quotes, reference data, headlines, and short interest come from Massive, formerly Polygon, a licensed market data vendor. The age of the quotes is shown at the top of every page. Insider trades, notable holders and profits come straight from the SEC. That means Form 4 filings, 13F filings and XBRL financial data on EDGAR. Government filings come from the public STOCK Act and Office of Government Ethics disclosures. The market-wide headlines on the market line also come from the public headline feeds CNBC, MarketWatch and Yahoo Finance publish, shown as the headline, the source and a link to the article. Splits, dividends, and the financial statements on each ticker page come from the vendor's reference data. The 8-K filings on EDGAR are read for the items that move a price. Five years of history is loaded for every stock. So the 200-day and 52-week traits rest on real history. Options flow is not part of the product.
What does it cost?
One plan with everything in it: $29 a month, $69 for three months, or $249 a year. You pick the billing period when the trial ends, and payments go through Stripe, so Breakaway never sees your card.
Is this investment advice?
No. It is a screening tool that scores stocks on the chart, the company's own results, and the news and filings. It does not know your situation and it is not a recommendation to buy or sell anything. Please do your own research.
The price, the score, the traits, and the industry rank on this page are delayed at least 15 minutes. Filings are shown as filed, because a disclosure is already days or weeks old when it becomes public. Earnings dates and past reactions are settled sessions.